고형암 (전체) | 바이오모아

ADCBiologicAstraZenecadeliveryPhase 3

Ceralasertib (Ceralasertib)

Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8 · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+5

효능 ORR 19%임상시험 41상태 RECRUITING

ADCBiologicMerck Sharp & Dohme LLCDeruxtecan in Patients With…Phase 2

I-DXd (Ifinatamab Deruxtecan, Ifinatamab Deruxtecan (I-DXd))

Carcinoma, Non-Small-Cell Lung · Small-Cell Lung Cancer

#Small-CellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+5

임상시험 41상태 RECRUITING

CGTBiologicImmunityBio, Inc.Phase 2

haNK (haNK)

Melanoma · Merkel Cell Carcinoma

#MerkelCellCarcinoma#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 5%임상시험 40상태 DISCONTINUED

CGTBiologicCARsgen Therapeutics Co., Ltd.Preclinical

CAR-GPC3 T Cells (CAR-GPC3 T Cells)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Preclinical#세포유전치료#CAR-T+3

효능 ORR 50%임상시험 39상태 ACTIVE

AntibodyGruppo Oncologico del Nord-OvestPhase 2

Botensilimab (Botensilimab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3

임상시험 38상태 RECRUITING

AntibodyHoffmann-La RochePhase 2

Hu5F9-G4 (Magrolimab, Magrolimab (Hu5F9-G4))

Urothelial Carcinoma; Bladder Cancer · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase2#항체#면역항체+4

효능 ORR 81.3%임상시험 35상태 ACTIVE

ADCBiologicMirati Therapeutics Inc.Phase 3

Sitravatinib (Sitravatinib)

Clear Cell Renal Cell Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 33.3%임상시험 35상태 DISCONTINUED

AntibodyMerckVedotin or Chemotherapy in …Phase 2

pembrolizumab (Keytruda, Pembrolizumab - anti-PD-1 antibody)

Solid Tumor, Adult · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+5

효능 ORR 11%임상시험 32상태 RECRUITING

AntibodyAnaveon AGVedotin ± Pe…Phase 2

KEYTRUDA® (ANV600 + pembrolizumab, ANV600 + pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+4

효능 ORR 71.4%임상시험 31상태 RECRUITING

ADCBiologicBeOne MedicinesPhase 1

Anticancer Agents (Anticancer Agents)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

효능 0%임상시험 31상태 RECRUITING

ADCBiologicstaleAmgenPhase 2

Intensity-Modulated Radiotherapy (Intensity-Modulated Radiotherapy)

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 38%임상시험 31상태 RECRUITING

ADCBiologicstaleMing-Yuan ChenPhase 3

Neoadjuvant and Adjuvant Immunotherapy (Neoadjuvant and Adjuvant Immunotherapy)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#LocallyAdvancedHeadandNeckSquamo#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 10%임상시험 31상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 2

Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3

임상시험 31상태 RECRUITING

ADCBiologicstaleAtreca, Inc.Preclinical

PD-1 and PD-L1 inhibitor (PD-1 and PD-L1 inhibitor)

Immune-related Adverse Event; Malignant Solid Tumors · PD-1

#PD-1#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 59%임상시험 31상태 RECRUITING

ADCBiologicstaleBioNTech SEPhase 2

Paroxetine (Paroxetine)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 31상태 RECRUITING

ADCBiologicstaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Enfortumab Vedotin)

Bellini Carcinoma; Collecting Duct Carcinoma · Bellini Carcinoma

#BelliniCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

효능 ORR 6%임상시험 31상태 RECRUITING

ADCBiologicstaleCastilla-La Mancha Health Servi…Phase 2

Perioperative treatment (Perioperative treatment)

Hepatoid Adenocarcinoma of Stomach · Hepatoid Adenocarcinoma of Stomach

#HepatoidAdenocarcinomaofStomach#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 31상태 RECRUITING

ADCBiologicstaleAstraZenecaPhase 3

Rilvegostomig (Rilvegostomig)

Hepatocellular Carcinoma · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2

임상시험 31상태 RECRUITING

ADCBiologicstaleMerck Sharp & Dohme LLCPhase 1

sacituzumab govitecan (Trodelvy, Sacituzumab)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

효능 ORR 33.3%임상시험 31상태 ACTIVE

ADCBiologicstaleAscendis Pharma Endocrinology D…Preclinical

Targeted drugs (Targeted drugs)

Immune-related Adverse Event; Malignant Solid Tumors · Immune-related Adverse Event

임상시험 31상태 RECRUITING

7 / 46 페이지

← 이전 다음 →

갱신 기록 없음 · 14일 주기 · 방문 0 / 568